CYP3A43 Antibody

What is CYP3A43 and what are its primary biological functions?

CYP3A43 is a member of the cytochrome P450 3A subfamily, which includes key oxidative enzymes involved in the metabolism of various carcinogens and anticancer drugs. While less studied than other CYP3A family members (CYP3A4, CYP3A5, and CYP3A7), CYP3A43 exhibits low testosterone 6-beta-hydroxylase activity and participates in the metabolism of endogenous steroids and exogenous compounds .

The protein is approximately 57-58 kDa and functions as a peripheral membrane protein primarily localized to the endoplasmic reticulum and microsomal membranes . Its highest expression is found in the prostate, with notable expression also occurring in the liver, kidney, pancreas, fetal liver, and fetal skeletal muscle .

How does CYP3A43 expression correlate with cancer development and progression?

CYP3A43 exhibits tissue-specific and context-dependent roles in cancer biology:

• In lung adenocarcinoma (LUAD): CYP3A43 expression is negatively correlated with cancer staging and lymph node metastasis, suggesting a tumor-suppressive role .

• In hepatocellular carcinoma: Low expression of CYP3A43 in tumor tissues has been associated with reduced median survival, suggesting it may serve as a promising predictive marker .

• In ovarian cancer: CYP3A43 expression is higher in cancerous tissues compared to normal ovary, though it has not been identified as an independent prognostic marker .

• In prostate cancer: Certain CYP3A43 polymorphisms (particularly CYP3A43*3 genotype/P340A; rs680055) correlate with increased cancer risk .

This dual role indicates that CYP3A43 may participate in cancer development in a tissue-specific manner .

What is the relationship between CYP3A43 and other CYP3A subfamily members?

The CYP3A subfamily (including CYP3A4, CYP3A5, CYP3A7, and CYP3A43) shows wide substrate specificity and participates in the metabolism of more than half of known drugs, endogenous steroids, and exogenous compounds .

An interesting regulatory relationship exists between CYP3A43 and CYP3A4. Research has identified a genomic region (R4) that appears to regulate these genes in opposing ways - deletion of R4 increases CYP3A4 expression while decreasing CYP3A43 expression . This suggests competitive domain-domain interactions within the CYP3A cluster, where deletion of R4 increases interaction between the CYP3A4 promoter and another regulatory region (R2) .

What are the validated antibodies and detection methods for studying CYP3A43?

Researchers have several validated tools for detecting CYP3A43:

For protein detection and quantification:

• Western blot (WB) using validated antibodies such as DF3584

• Immunofluorescence/Immunocytochemistry (IF/ICC) for cellular localization studies

For expression analysis:

• RT-PCR for mRNA quantification, as demonstrated in studies of CYP3A43 knockdown

• Real-Time Cell Analysis (RTCA) for monitoring cell viability and proliferation effects

How can researchers effectively establish CYP3A43 knockdown or overexpression models?

For stable knockdown:

• Design appropriate shRNA constructs targeting CYP3A43 (as demonstrated in H1299 cell line models)

• Verify knockdown efficiency at both protein level (via immunoblot) and mRNA level (via RT-PCR)

• Select cell clones with significant reduction in CYP3A43 expression (e.g., H1299-shCYP3A43-8# showed dramatic reduction compared to H1299-shctrl cells)

For transient overexpression:

• Utilize CYP3A43 expression plasmids for transfection into target cell lines (as demonstrated in A549 and HCC827 cells)

• Confirm overexpression via immunoblot analysis

• Proceed with functional assays within the appropriate time window for transient expression

What functional assays are most informative for investigating CYP3A43's role in cancer biology?

Proliferation assays:

• Real-Time Cell Analysis (RTCA) for continuous monitoring of cell proliferation

• Colony formation assays for assessing long-term effects on clonogenic ability

Migration assays:

• Wound healing assays to assess cell migration potential

In vivo models:

• Tumor xenograft models can validate in vitro findings and assess effects on tumor growth in a physiological context

Signaling pathway analysis:

• Immunoblotting for key signaling components (e.g., phosphorylated ERK1/2) can reveal mechanisms underlying CYP3A43's effects

How should researchers address contradictory findings regarding CYP3A43's role in different cancer types?

When addressing contradictory findings:

What challenges exist in studying CYP3A43's enzymatic activity and substrate specificity?

Key challenges include:

• Low expression levels: CYP3A43 is generally expressed at lower levels than other CYP3A family members, making detection and activity measurement challenging.

• Substrate overlap: The CYP3A subfamily shows wide substrate specificity, making it difficult to identify CYP3A43-specific substrates and activities.

• Isoform-specific tools: Limited availability of highly specific antibodies and inhibitors that can distinguish between CYP3A family members.

• Tissue-specific expression: Variable expression across tissues necessitates careful selection of experimental models relevant to the research question.

How can co-expression analysis enhance understanding of CYP3A43 function?

Co-expression analysis can provide valuable insights into CYP3A43 function:

• Identify functional networks: Research has identified genes with strong positive correlation to CYP3A43 expression, including PPP1R3E, NCRNA00202, and TTC14 .

• Context-specific interactions: Using databases like LinkedOmics to identify CYP3A43 co-expressed genes in specific cancer types (e.g., LUAD) .

• Pathway enrichment analysis: Following co-expression identification, perform GO and KEGG analyses to identify biological processes and pathways associated with CYP3A43 function .

• Regulatory relationships: Analysis of co-expressed genes can reveal potential upstream regulators or downstream effectors of CYP3A43, informing mechanistic studies.

What is the role of CYP3A43 in the ERK1/2 signaling pathway?

Research has established a connection between CYP3A43 and the ERK1/2 signaling pathway in LUAD:

• Inverse relationship: CYP3A43 expression appears inversely correlated with ERK1/2 phosphorylation levels. Specifically, when CYP3A43 is ectopically expressed in LUAD cell lines, decreased ERK1/2 phosphorylation is observed .

• Functional consequence: This suppression of ERK1/2 phosphorylation may mechanistically explain how CYP3A43 inhibits cell proliferation, as ERK1/2 is a key driver of cellular proliferation in many cancer types .

• Potential therapeutic target: Understanding the interaction between CYP3A43 and ERK1/2 signaling could provide new possibilities for targeted therapy of LUAD .

Researchers investigating this relationship should consider:

• Examining multiple components of the MAPK/ERK pathway to determine specificity

• Validating findings with ERK1/2 inhibitors to confirm pathway involvement

• Assessing whether the relationship is direct or involves intermediary factors

How do genetic polymorphisms in CYP3A43 affect cancer susceptibility and drug metabolism?

Several polymorphisms in CYP3A43 have been linked to cancer susceptibility:

• CYP3A43*3 genotype (P340A; rs680055): Associated with increased risk of prostate cancer .

• CYP3A43_74_delA (CYP3A43*2A, rs61469810): Shows significant association with tumor grade in breast cancer .

• SNP rs62471956 within regulatory region R4: The variant allele A has increased transcriptional activity, is associated with higher CYP3A43 expression, and lower CYP3A4 expression in liver samples .

These genetic variations may affect:

What emerging techniques might advance CYP3A43 research beyond current methodologies?

Several cutting-edge approaches could enhance CYP3A43 research:

• CRISPR-based genomic studies: The research has already demonstrated the utility of CRISPR-mediated deletions of genomic regions (e.g., R4) in understanding regulatory relationships between CYP3A genes . Further applications could include:

  • Precise modification of CYP3A43 coding sequence to study structure-function relationships

  • Creation of isogenic cell lines differing only in CYP3A43 status

  • Multiplex CRISPR screens to identify synthetic lethal interactions

• Chromatin conformation studies: Techniques like 4C and 3C assays have revealed interactions between regulatory regions and the CYP3A4 promoter . Similar approaches could elucidate the three-dimensional organization of the CYP3A locus and its impact on CYP3A43 regulation.

• Single-cell analysis: Single-cell RNA-seq and proteomics could reveal cell-to-cell variability in CYP3A43 expression and its correlation with cellular states or drug responses.

• Patient-derived organoids: These could provide more physiologically relevant models for studying CYP3A43 function in normal and diseased states.